stonks4u
Sign up free
ABOS logo

ABOS Acumen Pharmaceuticals, Inc.

NASDAQ Global Select · Biotechnology · Healthcare

$2.67
+0.12 (+4.71%)

Acumen Pharmaceuticals Inc. operates as a biopharmaceutical entity in the clinical development stage, dedicated to discovering and advancing therapeutic solutions for Alzheimer's disease. A key focus for the company involves progressing ACU193, an investigational targeted immunotherapy drug candidate. This particular humanized monoclonal antibody is currently undergoing initial human testing in Ph…

Market Cap: $192.85Macumenpharm.com

Price (90d)

No price history yet — the daily price refresh runs once a day.

Signal Score (90d)

100
100
Aug 12Aug 12

Quote

Day Range
$2.46 – $2.69
52-Week Range
$1.21 – $3.60
Volume
$518.0K
Market Cap
$192.85M
50-Day Avg
$2.37
200-Day Avg
$2.37
Prev Close
$2.55
Open
$2.48

Valuation & Ratios

P/E Ratio
-1.05
EPS
$-2.00
P/B Ratio
1.81
P/S Ratio
0.00
Debt/Equity
0.44
Current Ratio
4.07
Dividend Yield
+0.0%
Gross Margin
+0.0%

Returns & Efficiency

Return on Equity
-172.3%
Return on Assets
-98.8%
FCF Yield
-90.5%
EV/EBITDA
-0.90

Revenue & Net Income (Annual)

Fiscal YearRevenueNet IncomeEPS
2025$0.00$-121.33M$-2.00
2024$0.00$-102.33M$-1.71
2023$0.00$-52.37M$-1.08
2022$0.00$-42.86M$-1.06
2021$0.00$-100.61M$-2.63

Social Signal Score

51
5d
51
2 mentions
—
30d
51
2 mentions
—
60d
51
2 mentions
—
90d
51
2 mentions
—
news: 2

Earnings

Wed, Nov 11(in 3 months)

Consensus estimate $-0.41 per share

4of 7 quarters beat consensus

Typical surprise +14.3% (median, so one quarter with a near-zero estimate can't distort it)

  • Tue, Aug 11$-0.45 vs $-0.36miss
  • Tue, May 12$-0.33 vs $-0.40beat
  • Thu, Mar 26$-0.41 vs $-0.50beat
  • Wed, Nov 12$-0.44 vs $-0.63beat
  • Tue, Aug 12$-0.68 vs $-0.54miss
  • Tue, May 13$-0.48 vs $-0.56beat

Estimates and results for ABOS via Financial Modeling Prep. Beating consensus says the company cleared the bar analysts set, not that the business grew.

Valuation

ABOShas no positive reported earnings per share, so an earnings-multiple projection can't be built for it. Companies are valued on other measures at this stage — revenue growth, cash burn, or book value — none of which this calculator models.

Mentions (2)

  • Newsmarketbeat.com·3d ago·Neutral

    Acumen Pharmaceuticals Q2 Earnings Call Highlights Acumen Pharmaceuticals NASDAQ: ABOS said it remains on track to report top-line results late in 2026 from its Phase II ALTITUDE-AD study of sabirnetug, an investigational antibody designed to selectively target synaptotoxic amyloid-beta oligomers in early Alzheimer's disease.

    View source ↗
  • Newsglobenewswire.com·3d ago·Neutral

    Acumen Pharmaceuticals Reports Second Quarter 2026 Financial Results and Business Highlights NEWTON, Mass., Aug. 12, 2026 (GLOBE NEWSWIRE) -- Acumen Pharmaceuticals, Inc. (NASDAQ: ABOS) (“Acumen” or the “Company”), a clinical-stage biopharmaceutical company developing novel therapeutics that target toxic soluble amyloid beta oligomers (AβOs) for the treatment of Alzheimer's disease (AD), today reported financial results for the second quarter of 2026 and provided a business update.

    View source ↗